Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AURINIA PHARMACEUTICALS INC.

(AUPH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Health Care Stocks Drifting Near Unchanged Mark Monday

11/22/2021 | 01:56pm EST


ę MT Newswires 2021
All news about AURINIA PHARMACEUTICALS INC.
01/07AURINIA PHARMACEUTICALS INC. Regulation FD Disclosure, Financial Statements and Exhibi..
AQ
01/04Aurinia Pharmaceuticals to Present at Upcoming January Investor Conferences
BU
2021Oppenheimer Upgrades Aurinia Pharmaceuticals to Outperform From Perform, Adjusts PT to ..
MT
2021Aurinia Announces Positive Topline Results from the AURORA 2 Continuation study of LUPK..
AQ
2021AURINIA PHARMACEUTICALS : Clinical Program Update
PU
2021Health Care Stocks Lower Ahead of Thursday Open
MT
2021Aurinia Pharmaceuticals Reports Positive Update on Drug to Treat Active Lupus Nephritis
MT
2021AURINIA PHARMACEUTICALS INC. : Regulation FD Disclosure, Financial Statements and Exhibits..
AQ
2021Aurinia Announces Positive Topline Results From the AURORA 2 Continuation Study of LUPK..
BU
2021Aurinia Announces Positive Topline Results from the Aurora 2 Continuation Study of Lupk..
CI
More news
Analyst Recommendations on AURINIA PHARMACEUTICALS INC.
More recommendations
Financials (USD)
Sales 2021 44,7 M - -
Net income 2021 -182 M - -
Net cash 2021 254 M - -
P/E ratio 2021 -10,3x
Yield 2021 -
Capitalization 1 900 M 1 900 M -
EV / Sales 2021 36,8x
EV / Sales 2022 8,62x
Nbr of Employees 294
Free-Float -
Chart AURINIA PHARMACEUTICALS INC.
Duration : Period :
Aurinia Pharmaceuticals Inc. Technical Analysis Chart | AUPH | CA05156V1022 | MarketScreener
Technical analysis trends AURINIA PHARMACEUTICALS INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 14,65 $
Average target price 33,63 $
Spread / Average Target 130%
EPS Revisions
Managers and Directors
Peter S. Greenleaf President, Chief Executive Officer & Director
Joseph M. Miller Chief Financial Officer
George M. Milne Chairman
Robert B. Huizinga Executive Vice President-Research
Neil Solomons Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
AURINIA PHARMACEUTICALS INC.-35.94%1 900
GILEAD SCIENCES, INC.-7.35%84 382
REGENERON PHARMACEUTICALS-4.16%63 645
VERTEX PHARMACEUTICALS3.93%58 082
WUXI APPTEC CO., LTD.-12.95%47 040
BIONTECH SE-40.05%37 325